Carbidopa

Catalog No.S1891

For research use only.

Carbidopa is an aromatic-L-amino-acid decarboxylase inhibitor with an IC50 of 29 ± 2 μM.

Carbidopa Chemical Structure

CAS No. 28860-95-9

Selleck's Carbidopa has been cited by 3 Publications

Purity & Quality Control

Choose Selective Decarboxylase Inhibitors

Biological Activity

Description Carbidopa is an aromatic-L-amino-acid decarboxylase inhibitor with an IC50 of 29 ± 2 μM.
Targets
aromatic-L-amino-acid decarboxylase [1]
29 μM

Protocol (from reference)

Solubility (25°C)

In vitro

DMSO 4 mg/mL
(17.68 mM)
Water Insoluble
Ethanol Insoluble

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
4% DMSO+30% PEG 300+2% Tween 80+ddH2O
For best results, use promptly after mixing.

1mg/mL

Chemical Information

Molecular Weight 226.23
Formula

C10H14N2O4

CAS No. 28860-95-9
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05094050 Recruiting Drug: ABBV-951 Parkinson''s Disease AbbVie December 9 2021 Phase 1
NCT05128175 Recruiting Drug: WD-1603 Carbidopa-Levodopa Extended-Release Tablets Parkinson Disease Shanghai WD Pharmaceutical Co. Ltd. October 29 2021 Phase 1
NCT03887884 Completed Drug: CVT-301|Drug: Sinemet Parkinson''s Disease Acorda Therapeutics March 5 2019 Phase 1
NCT03665454 Completed Drug: PF-06412562|Drug: Standard of Care Placebo Parkinson Disease Milton S. Hershey Medical Center|Pfizer September 24 2018 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Carbidopa | Carbidopa supplier | purchase Carbidopa | Carbidopa cost | Carbidopa manufacturer | order Carbidopa | Carbidopa distributor